Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836288 · ClinicalTrials.gov registry record · Early Phase 1
Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer
A Early Phase 1 study of Depression and Cancer, sponsored by Scott A. Irwin, MD, PhD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT02836288: Completed Early Phase 1 study of Depression and Cancer, sponsored by Scott A. Irwin, MD, PhD.
NCT02836288 is a Early Phase 1 study of Depression and Cancer that has completed, run by Scott A. Irwin, MD, PhD. The registered enrollment target is 4 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02836288, a Early Phase 1 study of Depression and Cancer, has completed, sponsored by Scott A. Irwin, MD, PhD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to see if it is safe to give patients with cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation, chemotherapy, and/or surgery for their cancer treatment to treat depression and its effects. Researchers would also like to see if giving ketamine at the same time as cancer treatment is practical and reasonably acceptable to the patient. Depression has many negative consequences for outcomes in those with cancer. It causes delayed treatments, increases in hospital lengths of stay, decreases in treatment adherence, poorer self-care, and decreased quality of life, even at 3 years post treatment. The presence of depression is the number one predictor of incomplete treatment and difficulty with rehabilitation. Therefore, investigators would also like to see if it is feasible to give patients ketamine during their routine cancer treatment treat depression and its negative effects on cancer treatment outcomes, and also help with anxiety, pain, and quality of life. The study will also use a placebo to compare to the good and/or bad effects of ketamine. A placebo is not an active drug and it will be look the same as ketamine, as a liquid to be taken by mouth. Ketamine is approved by the U.S. Food and Drug Administration (FDA) as a general anesthetic by itself for some diagnostic and surgical procedures or combined with other general anesthetic agents. It has also been shown to reduce cancer pain. Ketamine is considered experimental in this study because it is not approved by the FDA for the treatment of depression.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ketamine
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2018-05-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02836288
The ClinicalTrials.gov registry entry for NCT02836288 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (99% lower). The listed sponsor is Scott A. Irwin, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02836288 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02836288 about?
NCT02836288 is a clinical study titled "Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer". The primary purpose of this study is to see if it is safe to give patients with cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation, chemotherapy, and/or surgery for their cancer treatment to treat depression and its effects. Researchers would also ...
What is the current status of trial NCT02836288?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2016-12-20. Estimated completion is 2018-05-29.
What conditions does trial NCT02836288 study?
This clinical trial studies the following conditions: Depression, Cancer.
What interventions are being tested in trial NCT02836288?
The interventions under investigation include: Placebo (OTHER), Ketamine (DRUG).
Who is sponsoring clinical trial NCT02836288?
This trial is sponsored by Scott A. Irwin, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02836288 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
RECRUITING · Early Phase 1
-
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
RECRUITING · Early Phase 1
-
Probiotic Administration for Adolescent Depression
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
ACTIVE NOT RECRUITING · Early Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.